Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes

Neutralization of the inflammatory cytokine interleukin-1β (IL-1β) is a promising new strategy to prevent the β-cell destruction, which leads to type 2 diabetes. Here, we describe the preclinical development of a therapeutic vaccine against IL-1β consisting of a detoxified version of IL-1β chemicall...

Full description

Bibliographic Details
Main Authors: Gunther Spohn, Christian Schori, Iris Keller, Katja Sladko, Christina Sina, Reto Guler, Katrin Schwarz, Pål Johansen, Gary T Jennings, Martin F Bachmann
Format: Article
Language:English
Published: Elsevier 2014-01-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050116301164

Internet

http://www.sciencedirect.com/science/article/pii/S2329050116301164

Similar Items